Clinical trial of epirubicin vs mitomycin bladder instillation chemotherapy for the treatment of superficial bladder cancer

VernacularTitle:膀胱内灌注丝裂霉素与表柔比星预防膀胱癌术后复发的临床研究
Author: Mei-Feng LI ¹ ; Xiao-Qing ZHOU ; Qing ZENG ; Song-Tao LUO
Author Information

1. 丽水市人民医院泌尿外科
Keywords: mitomycin; epirubicin; bladder carcinoma; instillation chemotherapy; follow-up period
From: The Chinese Journal of Clinical Pharmacology 2014;(6):500-502
CountryChina
Language:Chinese
Abstract: Objective To evaluate the clinical efficacy and adverce drug reaction ( ADR ) for epirubicin and mitomycin bladder instillation chemotherapy in the treatment of superficial bladder cancer ( SBC ).Methods Seventy-eight cases of postsurgical SBC recruited from Apr 2011 to Jan 2013 in our hospital retrospectively.Of the 78 subjects , 31 patients were treated by mitomycin and other 47 cases were treated by epirubicin.The clinical efficacy and ADR of the two groups were recor-ded and compared.Results The median follow-up period of mitomy-cin group was 12.6 months with a recurrence rate of 16.1%( 5/31 ).And the median follow -up period of epirubicin group was 13.2 months with a recurrence rate of 14.7%(7/47).No statistical difference of re-currence of hazard ratio ( HR=1.02 ) was found between the two groups ( P>0.05).Conclusion There were no statistical difference for epiru-bicin and mitomycin bladder instillation chemotherapy in the treatment of superficial bladder cancer.